Codex DNA (NASDAQ:DNAY – Get Rating) is one of 42 public companies in the “Analytical instruments” industry, but how does it weigh in compared to its rivals? We will compare Codex DNA to related businesses based on the strength of its risk, valuation, profitability, institutional ownership, dividends, earnings and analyst recommendations. Institutional & Insider Ownership […]
Codex DNA (NASDAQ:DNAY – Get Rating) is one of 42 public companies in the “Analytical instruments” industry, but how does it contrast to its competitors? We will compare Codex DNA to related businesses based on the strength of its earnings, dividends, institutional ownership, profitability, risk, valuation and analyst recommendations. Profitability This table compares Codex DNA […]
Codex DNA (NASDAQ:DNAY – Get Rating) is one of 43 public companies in the “Analytical instruments” industry, but how does it compare to its rivals? We will compare Codex DNA to similar companies based on the strength of its profitability, institutional ownership, valuation, dividends, risk, earnings and analyst recommendations. Profitability This table compares Codex DNA […]
Codex DNA (NASDAQ:DNAY – Get Rating) is one of 43 publicly-traded companies in the “Analytical instruments” industry, but how does it contrast to its peers? We will compare Codex DNA to similar companies based on the strength of its earnings, risk, institutional ownership, dividends, profitability, analyst recommendations and valuation. Institutional & Insider Ownership 87.6% of […]
02.06.2022 - SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) - Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that Todd R. Nelson, PhD, the company’s chief executive officer, will present at the 2022 .